Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of LNP023 in C3 glomerulopathy
2018-004253-24Phase 2Unknown
- Sponsor
- Novartis
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iptacopan in Complement 3 glomerulopathy (C3G), sponsored by Novartis. Primary endpoints: Primary composite 3-component renal response at 9 months and Composite 2-component renal response at 9 months. Status: unknown.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on 2018-004253-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004253-24.